The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000705381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
21/05/2026
Date registered
Help: Date registered
12/06/2026
Date last updated
Help: Date last updated
12/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/06/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Spontaneous breathing in respiratory failure evaluation (SABRE)
Scientific title
Spontaneous breathing in adults with acute hypoxaemic respiratory failure receiving invasive ventilation: an inception cohort
Additional trial identifiers [1] 317352 0
SABRE
Universal Trial Number (UTN)
Trial acronym
SABRE (SpontAneous Breathing in Respiratory Failure Evaluation)
Related trial records

Health condition
Health condition(s) studied:
Acute Hypoxaemic Respiratory Failure 342012 0
Invasive Mechanical Ventilation 342013 0
Condition category
Condition code
Respiratory 338094 338094 0 0
Other respiratory disorders / diseases
Emergency medicine 338283 338283 0 0
Other emergency care

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
Spontaneous breathing is defined as a total respiratory rate above the set respiratory rate during invasive ventilation. Details from routinely collected data will be recorded for the purposes of the study retrospectively. These include ventilatory variables observed (Set and total respiratory rate, set and measured tidal volume, peak inspiratory pressures, positive end expiratory pressure (PEEP), and fraction of inspired oxygen (FiO2)), vital signs observed and recorded on the ICU medical record, specific treatments prescribed (Sedation, analgesia, vasoactive medications, neuromuscular blockade), and adjunctive treatments prescribed or used (Prone positioing, renal replacement therapy, extracorporeal membrane oxygenation, tracheostomy, extubation, and reintubation) for the first five days from enrolment, Outcome data will be collected at day 28 including duration of invasive ventilation, and mortality, Patients will not be participating in questionnaires.
Intervention code [1] 334144 0
Not applicable
Description of the comparator or control
Mandatory ventilation defined as a total respiratory rate equalling the set respiratory rate during invasive ventilation.

Spontaneous breathing is defined as a total respiratory rate above the set respiratory rate during invasive ventilation. Details from routinely collected data will be recorded for the purposes of the study retrospectively. These include ventilatory variables observed (Set and total respiratory rate, set and measured tidal volume, peak inspiratory pressures, positive end expiratory pressure (PEEP), and fraction of inspired oxygen (FiO2)), vital signs observed and recorded on the ICU medical record, specific treatments prescribed (Sedation, analgesia, vasoactive medications, neuromuscular blockade), and adjunctive treatments prescribed or used (Prone positioing, renal replacement therapy, extracorporeal membrane oxygenation, tracheostomy, extubation, and reintubation) for the first five days from enrolment, Outcome data will be collected at day 28 including duration of invasive ventilation, and mortality, Patients will not be participating in questionnaires.
Control group
Active

Outcomes
Primary outcome [1] 345494 0
Proportion of patients with spontaneous breathing activity (Total respiratory rate > Set respiratory rate) on days 1, 2, and 3.
Timepoint [1] 345494 0
Days 1,2, and 3 of enrolment in the study. Day 1 is the day of enrolment.
Secondary outcome [1] 461902 0
Tidal volume > 8 ml/kg predicted body weight on days 1, 2 and 3 following enrolment. Day 1 is the day of enrolment.
Timepoint [1] 461902 0
Days 1, 2, and 3 following enrolment. Day 1 is the day of enrolment.
Secondary outcome [2] 461903 0
Median time to first spontaneous breathing activity lasting 2 consecutive hours or longer
Timepoint [2] 461903 0
Days 1 - 5 following enrolment in the study. Day 1 is the day of enrolment.
Secondary outcome [3] 461904 0
Median time to continuous spontaneous ventilation (Set RR = 0) lasting 2 consecutive hours or longer.
Timepoint [3] 461904 0
Days 1-5 folowing enrolment. Day 1 is the day of enrolment.
Secondary outcome [4] 461905 0
Median percentage of spontaneous minute ventilation days 1,2, and 3.
Timepoint [4] 461905 0
Days 1, 2, and 3 folowing enrolment. Day 1 is the day of enrolment.
Secondary outcome [5] 461907 0
Median ventilator-free days at day 28
Timepoint [5] 461907 0
Day 28 following enrolment in the study. Day 1 is the day of enrolment.
Secondary outcome [6] 461908 0
Mortality at day 28 following enrolment in the study.
Timepoint [6] 461908 0
day 28 following enrolment in the study. Day 1 is the day of enrolment.
Secondary outcome [7] 461910 0
The incidence of patients with acute hypoxaemic respiratory failure receiving invasive ventilation in the ICU
Timepoint [7] 461910 0
At time of enrolment.

Eligibility
Key inclusion criteria
Eligible participants are patients that meet all the inclusion criteria below:
1) aged 18 or older
2) Receiving invasive ventilation and expected to remain invasively ventilated for at least 24 hours.
3) acute hypoxaemic respiratory failure, defined as one of the following criteria:
a) arterial partial pressure of oxygen measured on an arterial blood gas : Fraction of inspired oxygen < 300 mmHg
b) Peripheral pulse oxymeter saturations: Fraction of inspired oxygen < 315 mmHg (if peripheral oxygen saturations < 97%)
4) acute hypoxaemic respiratory failure onset on invasive ventilation in ICU within the last 24 hours
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1) Patient received invasive ventilation for > 72 hours at time of eligibility.
2) Patients admitted with a traumatic brain injury
3) Admission with severe life-threatening asthma
4) Previous medical history of severe chronic obstructive pulmonary disease (COPD)
5) Chronic or acute neuromuscular disease
6) Patients on extracorporeal membrane oxygenation (ECMO)
7) Patients admitted with an unsurvivable illness or potential organ donation.

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Convenience sample
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment outside Australia
Country [1] 28136 0
New Zealand
State/province [1] 28136 0

Funding & Sponsors
Funding source category [1] 321924 0
Charities/Societies/Foundations
Name [1] 321924 0
Australian and New Zealand Intensive Care Foundation
Country [1] 321924 0
Australia
Funding source category [2] 321925 0
Charities/Societies/Foundations
Name [2] 321925 0
Heart Lung Foundation
Country [2] 321925 0
New Zealand
Funding source category [3] 321926 0
Charities/Societies/Foundations
Name [3] 321926 0
Auckland Hospital Research and Endowment Fund
Country [3] 321926 0
New Zealand
Funding source category [4] 321927 0
Charities/Societies/Foundations
Name [4] 321927 0
Royal Australasian College of Physicians Foundation
Country [4] 321927 0
New Zealand
Primary sponsor type
Other
Name
Medical Research Institute of New Zealand
Address
Country
New Zealand
Secondary sponsor category [1] 324795 0
None
Name [1] 324795 0
Address [1] 324795 0
Country [1] 324795 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320463 0
Central Health and Disability Ethics Committee
Ethics committee address [1] 320463 0
Ethics committee country [1] 320463 0
New Zealand
Date submitted for ethics approval [1] 320463 0
23/08/2025
Approval date [1] 320463 0
15/09/2025
Ethics approval number [1] 320463 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150550 0
Dr Dilip Jayasimhan
Address 150550 0
Auckland City Hospital, 2 Park Road, Grafton, Auckland 1023
Country 150550 0
New Zealand
Phone 150550 0
+642102270930
Fax 150550 0
Email 150550 0
Contact person for public queries
Name 150551 0
Dilip Jayasimhan
Address 150551 0
Auckland City Hospital, 2 Park Road, Grafton, Auckland 1023
Country 150551 0
New Zealand
Phone 150551 0
+642102270930
Fax 150551 0
Email 150551 0
Contact person for scientific queries
Name 150552 0
Dilip Jayasimhan
Address 150552 0
Auckland City Hospital, 2 Park Road, Grafton, Auckland 1023
Country 150552 0
New Zealand
Phone 150552 0
+642102270930
Fax 150552 0
Email 150552 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
A finite period of: 5 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocol    SABRE-NZ Protcol Version 1.1 (100126) (copy).docx


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.